364 related articles for article (PubMed ID: 36013536)
1. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the prognosis of resected early-stage patients with non-small cell lung cancer: A meta-analysis.
Cao W; Yu H; Zhu S; Lei X; Li T; Ren F; Zhou N; Tang Q; Zu L; Xu S
Cancer Med; 2023 Mar; 12(6):7065-7076. PubMed ID: 36480232
[TBL] [Abstract][Full Text] [Related]
7. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis.
Matsas S; Aguiar PN; Del Giglio A
J Gastrointest Oncol; 2024 Feb; 15(1):33-51. PubMed ID: 38482212
[TBL] [Abstract][Full Text] [Related]
9. Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy.
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Robinson A; Baetz T
Immunotherapy; 2020 Aug; 12(11):785-798. PubMed ID: 32657234
[No Abstract] [Full Text] [Related]
10. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
Leng J; Wu F; Zhang L
Front Oncol; 2022; 12():734948. PubMed ID: 35651788
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Petrova MP; Eneva MI; Arabadjiev JI; Conev NV; Dimitrova EG; Koynov KD; Karanikolova TS; Valev SS; Gencheva RB; Zhbantov GA; Ivanova AI; Sarbianova II; Timcheva CV; Donev IS
Biosci Trends; 2020 Mar; 14(1):48-55. PubMed ID: 32023563
[TBL] [Abstract][Full Text] [Related]
13. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients.
Wu G; Yao Y; Bai C; Zeng J; Shi D; Gu X; Shi X; Song Y
Thorac Cancer; 2015 May; 6(3):275-87. PubMed ID: 26273373
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of preoperative lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: a systematic review and meta-analysis.
Shao Y; Li W; Wang D; Wu B
World J Surg Oncol; 2020 Oct; 18(1):273. PubMed ID: 33097052
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.
Guo W; Lu X; Liu Q; Zhang T; Li P; Qiao W; Deng M
Cancer Med; 2019 Aug; 8(9):4135-4148. PubMed ID: 31197958
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy.
Xia WY; Zhu XR; Feng W; Liu J; Wang JM; Lv CX; Zhang Q; Yu W; Cai XW; Fu XL
Transl Lung Cancer Res; 2020 Oct; 9(5):1996-2007. PubMed ID: 33209619
[TBL] [Abstract][Full Text] [Related]
19. Initial neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with inoperable locally advanced non-small-cell lung cancer.
Sun S; Qu Y; Wen F; Yu H
Biomark Med; 2020 Oct; 14(14):1341-1352. PubMed ID: 32808809
[No Abstract] [Full Text] [Related]
20. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
Front Oncol; 2022; 12():962173. PubMed ID: 36059629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
